Astra Zeneca gets nod for anticoagulant drug

AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organisation for the import and marketing of Andexanet Alfa. The therapy addresses life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors, says a company statement.FXa inhibitors are increasingly employed for preventing and treating thrombotic events, such as deep vein thrombosis and pulmonary embolism, as well as in patients at high risk of stroke due to atrial fibrillation. While these medications effectively prevent unwanted clot formation, they also elevate the risk of major bleeding, which can be life-threatening.